A fundamental event in the pathogenesis of prion disease is the conversion of cellular prion protein into an abnormally folded isoform (PrP Sc ), which is the infectious causative agent of disease. With progression of disease, PrP
Introduction
Prion diseases are a group of fatal neurodegenerative disorders that are caused by the transmissible misfolded isoform (PrP Sc ) of the cellular prion (PrP C ) [1] , including Creutzfeldt-Jakob disease of humans, bovine spongiform encephalopathy, and scrapie of sheep. PrP
Sc is a β-sheet rich conformer of PrP C and is partially resistant to protease. With progression of prion disease, PrP
Sc is replicated and accumulated in the brain, and neuronal dysfunction and death occur. Previous studies have shown that PrP-null mice neither develop the disease nor accumulate PrP Sc even after prions are inoculated into their brains [2, 3] . This indicates that replication and accumulation of PrP Sc are closely related to the pathogenesis of prion disease. Therefore, elucidation of the mechanisms of PrP Sc degradation and accumulation is critical for understanding the pathogenic mechanism of prion disease and for developing therapeutic agents.
PrP Sc usually accumulates excessively over PrP C in cultured cells and mouse brains (Figure 1 ). This strongly indicates that PrP Sc is protected against its proteolytic degradation. Actually, several studies have reported that the proteolytic systems (e.g., lysosomal degradation and ubiquitin-proteasomal degradation systems) are inhibited by prion infection [4] [5] [6] [7] , and PrP
Sc is found at the cell surface and in endosomal/lysosomal compartments [8] [9] [10] . Moreover, when PrP Sc was fractionated by detergent-based biochemical fractionation, most of the PrP Sc was detected in detergent-resistant membrane (DRM) fractions [11] , suggesting that PrP Sc mainly exists in membrane bound form and PrP Sc is degraded preferentially in lysosomes, but not by cytosolic proteasomes. PrP Sc to be degraded in lysosomes might be preferentially selected and directed into the lysosomal degradation pathway by dedicated membrane trafficking machinery. Therefore, knowledge of the mechanism that sorts PrP into late endosomal/lysosomal compartments should be important for understanding the accumulation of PrP Sc .
PrP
Sc accumulation Figure 1A shows the expression of total PrP and PrP Sc in uninfected and prioninfected mouse brains. In this figure, we can easily recognize that the total amount of PrP in infected mouse brains is larger than in uninfected mouse brains. In cultured cells, such excessive expression of total PrP in infected cells was also confirmed ( Figure 1B) . These results indicate that the amount of PrP Sc in infected cells is larger than PrP C in uninfected cells, and that PrP Sc is protected against proteolytic degradation.
Why is PrP Sc protected from proteolysis and over-accumulated? One possible reason is the protease resistance of PrP Sc that is attributed to its β-rich structure at the C-terminal region. If such protease resistance mainly affected the inhibition of PrP Sc degradation, most of the PrP Sc could be found in the lysosome, which contains various kinds of hydrolytic enzymes and is a major compartment responsible for the digestion of macromolecules such as proteins. The majority of PrP Sc is actually observed intracellularly, whereas PrP C mainly localizes to the cell surface (Figure 2A) . However, detailed analyses of its intracellular distribution show that PrP Sc is widely distributed in posttrans Golgi network (TGN) compartments [8] [9] [10] (Figure 2B ). From these 
Sortilin and other VPS10P domain receptors
PrP would have to move by transport vesicles in post-TGN compartments, including TGN, endosomes, lysosomes, and the plasma membrane. Then, in this transport network, the PrP to be degraded could be sorted into transport carriers bound for late endosomal/lysosomal compartments. For this purpose, a sorting receptor might be useful and required because it can select and concentrate a target cargo protein into transport carriers and promote transport carrier formation. In our recent study, Sortilin has been identified as a sorting receptor that directs PrP into late endosomal/lysosomal compartments. Sortilin is a member of the VPS10P domain receptor family, which is comprised of five members (Sortilin, SorCS1, SorCS2, SorCS3, and SorLA). In this section, briefly, we describe Sortilin and other VPS10P receptors and their implications for neurodegenerative diseases. VPS10P-domain receptors are multiligand type-I transmembrane proteins. They contain five members, Sortilin, SorLA, SorCS1, SorCS2, and SorCS3, and deliver a number of target cargo proteins to their destinations, interacting with them via VPS10P domains on the luminal/extracellular N-terminus (Figure 3) . The whole luminal/extracellular region in Sortilin is composed of a simple VPS10P domain, but other receptors have additional modules (Figure 3) .
VPS10P-domain receptors are expressed in the brain and are involved in neuronal function and viability [12, 13] . Sortilin binds to progranulin and mediates endocytosis and delivery of progranulin into lysosomes [14] , and rare nonsynonymous variants in SORT1 increase the risk for frontotemporal lobar degeneration [15] . Sortilin also mediates trafficking of neuronal degeneration causative and related proteins. Sortilin has been identified as an amyloid precursor protein (APP) interaction partner and promotes α-cleavage of APP [16] . In addition, Sortilin interacts with BACE1, β-site APP cleavage enzyme 1, and mediates its retrograde trafficking from the plasma membrane to TGN via early endosomes [17] . It has been suggested that Sortilin is potentially associated with Parkinson's disease [18] . Moreover, recently, it has been reported that Sortilin is involved in tau prion replication [19] .
As for other VPS10P receptors, it has been reported that SorLA is associated with sporadic and late-onset Alzheimer's disease (AD) [5, 20] . SorLA directs APP into the recycling pathway and protects APP from β-cleavage resulting in Aβ generation [5, 21, 22] . On the other hand, loss of SorLA shifts the traffic flow of APP to the late endosomal pathway and facilitates β-cleavage of APP and Aβ-generation [5, 21, 22] . In addition, a meta-analysis indicated that multiple SorLA variants are associated with the risk of Alzheimer's disease [23] . SorCS1 is also involved in APP transport and Aβ-generation and is identified as a risk factor for Alzheimer's disease [24, 25] . Variants of SorCS2 and SorCS3 are also associated with the risk of Alzheimer's disease [24, 25] . Although a number of studies have indicated that VPS10P-domain receptors are implicated in neurodegenerative diseases and their impairment could be a risk factor for diseases, the relation between VPS10P receptors and prion disease is not known.
Role of Sortilin in PrP trafficking
Sortilin has been identified as a novel PrP-binding protein and is colocalized with PrP C both at the cell surface and intracellular compartments [11] . In Sortilinknockdown (Sortilin-KD) uninfected cells, most of the PrP C is localized at the cell surface, and PrP C expression is increased. In addition, a PrP C uptake experiment, in which cell surface PrP C was labeled with anti-PrP antibody and internalized labeled PrP C was measured after incubation, demonstrated that PrP C internalization was weakened by Sortilin-KD [11] . These results indicate that Sortilin acts as a cell surface receptor for PrP C endocytosis. PrP C was also colocalized with Sortilin intracellularly [11] . This made us recollect that Sortilin could function intracellularly as a sorting receptor for PrP trafficking. When the internalized labeled PrP C was costained for either Rab9 (a late endosomal marker) or Rab11 (a recycling endosomal marker) by indirect immunofluorescence, the internalized PrP C distributed to both late and recycling endosomes in control cells, whereas, in Sortilin-depleted cells, it failed to localize to late endosomes, and most of the internalized PrP C is localized to recycling endosomes [11] . These observations indicate that Sortilin is also required for sorting of PrP C into late endosomes to degrade it. Moreover, when wild type (wt) and Sortilin-knockout (ΔSort) cells were treated with NH 4 Cl, which increases lysosomal pH and inhibits proteolytic enzymes in lysosomes, PrP C was effectively accumulated in wt but not in ΔSort cells [11] , and PrP C colocalization with LAMP1, a lysosomal marker, in NH 4 Cl-treated ΔSort cells was significantly lower than NH 4 Cl-treated wt cells [11] . These results suggest that ΔSort cells failed to transport PrP C properly into lysosomes. Altogether, it could be concluded that Sortilin functions as a cell surface receptor for PrP C internalization and a sorting receptor to direct PrP C to lysosomes via late endosomes (Figure 4) . We would be able to extend such a role of Sortilin in PrP C trafficking to PrP Sc because Sortilin directly interacted with PrP C through its highly flexible N-terminal domain and anti-Sortilin antibody coprecipitated both PrP C and PrP Sc . In practical terms, Sortilin is implicated in PrP Sc degradation. The inhibition of Sortilin inhibited PrP C internalization by ~20% in the PrP C uptake assay [11] . This result raises a question. Why is PrP C endocytosis inhibited partially even when Sortilin function is almost or completely abolished [11] ? There are suggestive findings to answer this question. We examined the PrP distribution in uninfected wt cells and in uninfected ΔSort cells by detergent-based biochemical fractionation. Sixty three percent of PrP C in wt cells was detected in detergent resistant membrane (DRM) fractions, generally recognized as raft fractions, but thirtyseven percent of PrP C was also found in detergent soluble (nonraft) fractions [11] . Sortilin deficiency changed the PrP C distribution, and PrP C in nonraft fractions was reduced to ~15% in ΔSort cells [11] . At present, it is thought that both lipid raft-and clathrin-mediated endocytosis execute PrP C internalization [13, 26] . Sortilin was mostly isolated in nonraft fractions [11] . It has been reported that the cytoplasmic tail of Sortilin can interact with clathrin-associated adaptor protein complex, AP-2, at the plasma membrane and facilitate clathrin-mediated endocytosis [13, 27, 28] . We showed that the recombinant PrP devoid of its N-terminal domain (residues 23-88) (PrPΔ23-88) did not bind to Sortilin. Additionally, internalization and lysosomal degradation of PrPΔ23-88 were inhibited, and it accumulated at the cell surface [11] . These results are in good agreement with a previous report: the N-terminal domain (residues 23-107) of PrP C is sufficient for its endocytosis mediated by clathrin [29] . It is therefore inferred that Sortilin internalizes PrP C from nonraft domains at the cell surface by clathrin-coated vesicles. Moreover, it has been shown that the expression of total PrP C was not changed even when the flotillin-1-mediated lipid raft-dependent endocytosis of PrP C was inhibited by the knockdown of flotillin-1 [30] . Their and our results suggest that Sortilin-mediated endocytosis directs PrP C into the late endosomal/lysosomal degradation pathway, whereas PrP C that is internalized from the lipid raft domain in a Sortilin-independent manner largely enters the recycling pathway (Figure 4 ).
Dysfunction of Sortilin by prion infection
Sortilin expression also affects PrP Sc levels. Sortilin-KD increased PrP Sc in prion infected cells, similarly to PrP C in uninfected cells [11] . On the contrary, overexpression of Sortilin in infected cells reduced PrP Sc [11] . Furthermore, when we investigated PrP Sc accumulation in Sort1 +/+ and Sort1 −/− mouse brains after intracerebral prion inoculation, PrP Sc levels in Sort1 −/− mouse brains were significantly higher than in Sort1 +/+ mouse brains at the early stages of disease (at 45, 60, 90 dpi) [11] , suggesting an inhibition of PrP Sc degradation. Namely, dysfunction of Sortilin causes excessive accumulation. If so, does prion infection inhibit Sortilin function? Notably, Sortilin in infected cells was ~50% lower than in uninfected cells [11] . Moreover, in infected mouse brains at terminal stage, Sortilin also fell to ~45% as compared with age-matched uninfected mice [11] . These observations suggested that prion infection downregulated Sortilin expression. To confirm this, uninfected cells were treated with RML prion-infected mouse brain homogenate, and Sortilin and PrP Sc in individual cells were visualized by double immunofluorescence staining at 9 dpi ( Figure 5) . In cells displaying bright green signals derived from PrP Sc , little Sortilin (red) was detected, whereas the bright red fluorescence of Sortilin was observed in the others; that is, Sortilin expression was reduced by prion infection. To clarify why Sortilin is reduced by prion infection, we examined mRNA transcript levels by RT-PCR. There was little difference in Sortilin mRNA abundance between uninfected and infected cells. This suggested that the degradation of Sortilin was facilitated in prion infected cells. Hence, we treated cells with inhibitors of proteolytic degradation. The expression of Sortilin was almost the same in both untreated and MG132-treated cells but increased in NH 4 Cl-treated cells [11] . In particular, Sortilin expression was dramatically improved in NH 4 Cl-treated prioninfected cells, and another lysosomal inhibitor, concanamycin A, also improved Sortilin expression in infected cells [11] , suggesting that Sortilin is over-degraded in prion-infected cells in lysosomes.
Conclusions
Sortilin has been identified as a novel PrP-binding protein and functions as a sorting receptor to direct PrP into late endosomal/lysosomal compartments. © 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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